coplug
    Back to PCN explorer
    PCN reports · Core20PLUS5

    Knutsford PCN, Cheshire East (LAD) · Health Inequalities Profile

    PCN U06000 · NHS Cheshire and Merseyside Integrated Care Board · 1 GP practice

    Read the report

    This report is generated by Coplug's Healthcare Agent. Log in to ask further questions of it, add the spatial context, or create new enquiries to better understand and improve your Neighbourhood's Health

    01 / 15

    Board summary

    Key figures

    23,827

    Registered population

    55.3% aged 18–64

    25.6%

    Aged 65+

    ICB 19.0% · England 17.9%

    5.0%

    Ethnic minority (non-White)

    2.3% Asian · England 9.6%

    9.2%

    In IMD quintile 1

    ICB 31.9% · England 21.0%

    ~1,791

    Core20 residents (est.)

    Resident basis; registered basis ~2,204 · see page 3

    5,270

    Hypertension register

    +9.71% in 3 yrs · England +5.60%

    205

    SMI register

    5.2% of Cheshire East (LAD)'s

    393

    COPD register

    Reviews +8.94% in 3 yrs

    Forecast to 2030

    6,645

    Hypertension patients, 2030

    +1,375 on today

    67.1%

    QRISK ≥20% on statins, 2030

    +3.36pp over 3 yrs

    8.2%

    Cancer prevalence, 2030

    England 4.5%

    Three things the board should see

    61.0%
    Lipid therapy trails England across high-risk cohorts.

    Lipid-lowering therapy in CKD is 61.0% (England 70.3%), alongside shortfalls in diabetes with CVD (76.9% vs 84.4%) and QRISK ≥ 20% (59.8% vs 63.6%).

    61.4%
    Asthma annual reviews trail England and borough.

    Asthma reviews reach 61.4% against 64.5% in Cheshire East (LAD) and 65.7% in England, leaving a scale indicator of about 670 of 1,735 patients.

    72.9%
    Hypertension target control and COPD reviews lead.

    Hypertension treatment to target is 72.9% (England 70.3%; Cheshire East (LAD) 69.8%), while annual COPD reviews reach 89.3% against 76.4% in England.

    Sources & context

    PCN and practice-level primary care data; ICB and provider context on page 8

    Powered by Coplug · Page 1 of 15
    02 / 15

    Population, age and ethnicity

    Older population with 25.6% aged 65+ may elevate frailty and care-home demand

    Knutsford PCN serves 23,827 registered patients at Knutsford Medical Partnership. Older adults aged 65+ make up 25.6% (6,100 patients), well above Cheshire East (22.6%), the ICB (19.0%) and England (17.9%). The PCN catchment includes 15 care homes with 966 beds, while list size is projected to grow 3.8% by 2030 (unverified methodology). Census usual residents in associated areas are 95.0% White (Cheshire East 94.4%, ICB 93.0%, England 81.1%) and 5.0% ethnic minority groups. This older profile may drive high frailty and multimorbidity demand, though resident Census ethnicity does not directly measure registered-patient demographics.

    Age profile

    0–1719.1%
    18–6455.3%
    65+25.6%

    65+: ICB 19.0%, England 17.9%

    Ethnicity

    White95.0%
    Asian2.3%
    Mixed1.8%
    Other0.5%
    Black0.5%

    Older people · falls rows are Cheshire East (LAD) local-authority (LA) data, not PCN

    MeasureLocalNorth WestEnglandPeriod
    Falls admissions, 65+, per 100,000 (Cheshire East LA)2,1292,0711,9582024/25
    Diabetes with frailty: HbA1c ≤75 mmol/mol (PCN)86.5%82.9%81.9%2024/25
    Diabetes without frailty: HbA1c ≤58 mmol/mol (PCN)62.8%56.6%57.4%2024/25
    Falls admissions, 65 to 79, per 100,000 (Cheshire East LA)9391,0219552024/25
    Falls deaths, all ages, per 100,000 (Cheshire East LA)14.818.214.82022‑24
    Sources & context

    Census 2021; Fingertips falls and diabetes. Falls are local-authority data. Ethnic minority = 100% minus White

    Powered by Coplug · Page 2 of 15
    03 / 15

    Deprivation and Core20

    Average deprivation is low at decile 7.3, but 9.2% remain in Core20 areas

    Knutsford PCN has an average IMD decile of 7.3 (Cheshire East 7.1, ICB 5.2, England 5.5), with 9.2% of registered patients in the Core20 cohort (Cheshire East 9.2%, ICB 31.9%, England 21.0%). This equates to 2,204 estimated registered patients at Knutsford Medical Partnership, alongside 1,791 associated residents across one decile-2 LSOA (including 465 aged 0–17 and 216 aged 65+). Validating patient addresses against resident postcodes is essential to reconcile denominators before targeting outreach.

    % of patients in IMD quintile 1, by practice

    Dashed line: England 21.0% · right column: Core20 patients, registered basis

    Knutsford Medical9.2% · 2,204 patients
    Sources & context

    Deprivation: Index of Multiple Deprivation, applied to registered patients

    Powered by Coplug · Page 3 of 15
    04 / 15

    PLUS groups and inclusion health

    PLUS groups and inclusion health

    205

    SMI register

    0.87% recorded prevalence

    244

    Learning disability register

    1.03% recorded prevalence

    15

    Care homes, 966 beds

    In the PCN catchment

    8.8%

    Provide unpaid care

    Cheshire East (LAD), Census 2021

    The PCN records 244 learning disability patients (1.0% vs Cheshire East 0.5%, ICB 0.6%, England 0.6%) and 205 on the severe mental illness register (0.9% vs Cheshire East 0.9%, ICB 1.1%, England 1.0%). Cheshire East local authority records 8.8% unpaid carers (Census 2021) and 10 rough sleepers (autumn 2025 snapshot).

    Severe mental illness: physical health checks

    Recorded SMI checks show 83.4% have documented BMI, though three-year progress fell 1.3 pp (England +5.1 pp), while BP checks reached 82.3% (England 83.4%). Trailing physical recording could reflect recall gaps, unconfirmed locally.

    Sources & context

    QOF registers; Census 2021 carers; care homes and homelessness as supplied. Carers and homelessness are local-authority data

    Powered by Coplug · Page 4 of 15
    05 / 15

    Clinical focus: hypertension and lipids

    Clinical focus: hypertension and lipids

    5,270

    Hypertension register

    +9.71%

    Register growth, 3 yrs

    Cheshire East (LAD) +6.54% · England +5.60%

    +3.64pp

    BP control, under 80

    ≤140/90 · −0.79pp aged 80+

    +1,375

    More patients by 2030

    Forecast 6,645 (26.86%)

    Hypertension case-finding and control

    Recorded hypertension prevalence is 22.3% (5,270 patients), exceeding Cheshire East (17.3%), the ICB (16.8%) and England (15.2%), alongside elevated stroke (3.8%) and heart failure (3.3%) registers. Overall blood pressure treatment to target reaches 72.9% (England 70.3%) and control under age 80 is 71.6% (England 67.8%). However, blood pressure control for patients aged 80 and over trails at 79.8% (England 81.2%), falling 1.0% over three years (England +2.2%), alongside a 0.7% drop in recent blood pressure recording (England +3.6%). Observation periods are unstated and crude prevalence is not age-adjusted. Hypertension management is strong overall, but trailing review trends among older patients highlight a key group needing systematic blood pressure reassessment.

    Lipids and statins

    Lipid-lowering therapy lags behind England in QRISK ≥ 20% at 59.8% (England 63.6%), CKD at 61.0% (England 70.3%) and diabetes with CVD at 76.9% (England 84.4%), falling 1.8% over three years (England +1.0%). Fewer at-risk patients receive lipid-lowering therapy than England rates imply, making structured recall audits the immediate priority.

    MeasureItemsCost / itemICBEnglandAnnual spend
    Lipid-modifying, 202658,968£1.60£1.71£1.86£94,349
    Cardiovascular (all), 202574,415£4.31£4.37£3.33£320,729

    In 2026, the PCN prescribed 58,968 lipid-modifying items at an average cost of £1.60 per item, compared to £1.72 in Cheshire East, £1.71 in the ICB and £1.86 in England, spending £15,332 less than at England's unit cost. Lower unit costs indicate the PCN spends less per item than England, though unit cost does not establish prescribing efficiency or formulary.

    Sources & context

    QOF hypertension register and BP control indicators; prescribing items and cost as supplied

    Powered by Coplug · Page 5 of 15
    06 / 15

    Clinical focus: respiratory, cancer register and children

    Clinical focus: respiratory, cancer register and children

    Respiratory

    +3.21%

    Asthma reviews, PCN 3-yr % change

    +4.44%

    Asthma reviews, England 3-yr % change

    +2.19%

    Asthma prevalence, PCN 3-yr % change

    Asthma recorded prevalence is 7.8% (1,735 patients), above England (6.6%), while 12-month reviews reach 61.4% (England 65.7%; Cheshire East 64.5%), leaving about 670 patients unreviewed. Conversely, COPD reviews reach 89.3% (England 76.4%), despite recorded prevalence of 1.7% (393 patients; England 1.9%, unadjusted gap +47 to +58). Prescribing of asthma management items for ages 5-19 is 1,541 per 1,000 (England 1,488). Divergent review rates could reflect differing recall protocols across disease pathways, unverified locally.

    Cancer register and children's immunisation

    Cancer prevalence is 6.0% (1,420 patients), above England (3.8%). In childhood immunisation (Q1 2025/26), 12-month 6-in-1 coverage is 83.9%, below the 95.0% target by 11.1 pp (England 91.0%). At age 5, MMR dose 1 reaches 96.7% but dose 2 is 88.3% (8.4 pp difference; England 82.8%). The infant shortfall and pre-school dose drop could reflect reminder timing, unconfirmed locally.

    Dashed line: 95% national coverage target · solid tick: England

    6-in-1 at 12 months83.9%

    England 91.0%

    6-in-1 complete primary course at 24 months90.9%

    England 92.2%

    MMR dose 1 at 24 months87.3%

    England 88.3%

    MMR dose 2 at age 588.3%

    England 82.8%

    4-in-1 pre-school booster at age 588.3%

    England 80.9%

    Sources & context

    QOF registers and review indicators; childhood immunisation coverage as supplied

    Powered by Coplug · Page 6 of 15
    07 / 15

    Early cancer diagnosis

    Early cancer diagnosis

    55.5%

    Cheshire and Merseyside ICB, stage 1–2

    55.3%

    England, 2022

    75%

    National ambition by 2028

    ~2,640

    Extra early-stage cases a year to reach the ambition

    Stage 1–2 share by cancer type, 2022Cheshire and Merseyside ICBEnglandNo usable stageStaged cancers
    Lung40.4%33.8%11%2,354
    Breast87.1%85.4%11%2,083
    Prostate52.3%53.2%12%2,037
    Bowel44.9%47.0%16%1,674
    Skin cancer86.9%87.8%21%932

    Knutsford PCN recorded cancer prevalence is 6.0% (1,420 patients), growing +16.7% over three years (England +9.0%, Cheshire East (LAD) +10.6%). Local screening coverage exceeds England for breast (80.9% vs 69.9%) and cervical screening aged 25–49 (76.4% vs 66.8%). In the wider system, NHS Cheshire and Merseyside ICB diagnosed 55.5% of cancers at stage 1 or 2 in 2022 (England 55.3%), below the 75.0% national ambition by 19.5 pp, representing about 2,640 extra early-stage cases across 13,490 staged tumours (72.8% known stage). Early staging varies from 40.4% in lung to 87.1% in breast cancer.

    Sources & context

    Stage at diagnosis: National Disease Registration Service

    Powered by Coplug · Page 7 of 15
    08 / 15

    Cancer waits, diagnostics and community services

    Cancer waits, diagnostics and community services

    Cancer waits and diagnostics, Jul 2026 (provisional)

    In July 2026 (provisional), Manchester University NHS Foundation Trust achieved 72.8% on the cancer 62-day referral to treatment standard, below the 85.0% standard by 12.2 pp (East Cheshire NHS Trust 53.4%, North Cheshire and Mersey NHS Foundation Trust 83.7%, NHS Cheshire and Merseyside Integrated Care Board 76.2%, England 71.2%). On the 28-day faster diagnosis standard, the trust reached 80.1% against the 75.0% standard (East Cheshire NHS Trust 81.1%, England 79.3%). Trust diagnostic 6+ week waits were 9.0% overall (East Cheshire NHS Trust 16.2%, England 23.1%), though gastroscopy reached 29.3%.

    Pathways within standard (%)ManchesterEast CheshireNorth Cheshire and MerseyCheshire and Merseyside ICBEngland
    28-day faster diagnosis (75%)80.0681.0880.2177.2579.32
    31-day treatment (96%)92.5496.3098.1795.7192.50
    62-day referral to treatment (85%)72.8553.4183.6776.2371.16
    Diagnostic waits over 6 weeks (%)ManchesterEast CheshireNorth Cheshire and MerseyEngland
    MRI11.6826.620.5321.40
    CT14.6611.492.329.92
    Echocardiography4.9126.2428.0428.48
    Colonoscopy4.5110.8515.9830.83
    Gastroscopy29.3510.2520.2429.02
    All 15 DM01 tests8.9816.176.3423.14
    Community services activityCheshire East residentsCheshire and Merseyside ICB
    Care contacts72,825541,280
    Referrals18,28097,150
    Patients with a contact21,910146,240

    Community services (residents of Cheshire East), Jun 2026 (provisional). In June 2026 (provisional), Cheshire East residents recorded 135,460 community care activities and 72,825 contacts across 21,910 patients (NHS Cheshire and Merseyside Integrated Care Board: 1,332,205 activities, 541,280 contacts, 146,240 patients). Adults aged 65+ accounted for 60.8% of borough contacts, with 18,280 community referrals. These borough-level data reflect wider community demand and are not PCN activity.

    Sources & context

    Waits and diagnostics: NHS England monthly statistics · ICB and provider data, not PCN

    Powered by Coplug · Page 8 of 15
    09 / 15

    Practice variation and patient experience

    Single-practice clinical QOF reaches 99.7% while appointment booking trails England at 63.2%

    Knutsford Medical Partnership achieved 93.1% overall QOF points (England 92.5%) and 99.7% in the clinical domain (England 97.1%) in 2025/26. However, vaccination and immunisation domain achievement reached only 41.0% (England 55.2%), while personalised care adjustments were 7.7% across all domains (England 10.0%). This highlights childhood and adult immunisation uptake as the primary operational gap.

    GP Patient Survey by practice

    PracticeResponses% in IMD Q1Phone easyRequest led to apptOverall good
    Knutsford Medical1739.265.3%63.2%77.0%
    England—~2156.9%71.6%76.7%
    Sources & context

    QOF achievement; GP Patient Survey, practice-level results

    Powered by Coplug · Page 9 of 15
    11 / 15

    What the data can't tell us: gaps and local assets

    What the data can't tell us: gaps and local assets

    Local assets and voluntary sectorPCNCheshire East (LAD)AssetPCNCheshire East (LAD)
    Care homes (catchment)15 (966 beds)n/aSchools (catchment)37n/a
    Children's centres114Places of worship34272
    Libraries116Day centres (VCS)n/a1
    Children and young people (VCS)n/a1Carers support groups (VCS)n/a1
    Primary schools (LA maintained)541Primary academies778
    Special schools15

    0 = the source returned zero. n/a = not held at this level. No data = no value returned; this does not mean zero.

    Sources & context

    Gaps are modelled estimates against benchmark rates; local assets as supplied

    Powered by Coplug · Page 11 of 15
    12 / 15

    Options for the PCN

    Options for the PCN

    Each option in full

    Option 1

    Structured asthma annual review recall

    Asthma 12-month reviews are 61.4% (Cheshire East (LAD) 64.5%, ICB 62.3%, England 65.7%) on a 1,735-patient register (7.8% prevalence), leaving about 670 patients unreviewed. For discussion: the PCN could run structured asthma recall using a single template, align inhaler prescribing checks with annual reviews, and test after-school or flexible slots. Low cost, quick to run.

    Evidence base: the annual asthma review is the process gap between the register and outcomes.

    Policy anchor: Core20PLUS5 chronic respiratory disease priority.

    Option 2

    COPD register and respiratory record review

    COPD QOF prevalence (all ages) is 1.7% (393 patients) against Cheshire East (LAD) 1.8%, NHS Cheshire and Merseyside Integrated Care Board 2.5% and England 1.9% (3-year change +0.9% vs England +2.6% and Cheshire East (LAD) +3.4%), giving an unadjusted benchmark gap of +47 to +58 patients. Moderate effort to run.

    Evidence base: the copd register is the cohort for spirometry-confirmed diagnosis, annual review and inhaler technique; register size and growth set the workload those interventions must cover.

    Policy anchor: Core20PLUS5 adults: chronic respiratory disease (COPD vaccination and exacerbation reduction); Tobacco and Vapes Bill: smokefree generation.

    Option 3

    Pharmacist-led lipid therapy recall audit

    Lipid-lowering therapy trails England in CKD (61.0% vs 70.3%, -9.3 pp), diabetes with CVD (76.9% vs 84.4%, -7.4 pp; 3-year change -1.8% vs +1.0%) and QRISK ≥ 20% (59.8% vs 63.6%, -3.8 pp). Moderate effort to run.

    Evidence base: delivery measure for eight care processes and three treatment targets; shortfall here is what shows up later as emergency admission.

    Policy anchor: NHS Diabetes Prevention Programme and the eight care processes / three treatment targets.

    Sources & context

    Options are the profile's; evidence base from Coplug's indicator catalogue

    Powered by Coplug · Page 12 of 15
    13 / 15

    Provenance and audit trail

    Provenance and audit trail

    Figures are the profile's, drawn from Coplug indicator tables: census, deprivation and QOF measures, MHCLG, Rough sleeping snapshot in England: autumn 2025, OHID, Fingertips diabetes by frailty status: HbA1c control (93712, 93713) and OHID, Fingertips falls: emergency admissions, 65+ and 65 to 79 (22401, 22402), accidental-fall deaths (94002). Every recommended action and option is the profile's own; the evidence-base statements that support them — what each register is the cohort for, and the national policy it serves — are quoted from Coplug's indicator catalogue. No recommendation in this report is authored outside the profile and that catalogue. ICB- and provider-level data (page 8) describes the system the PCN sits in and is not read as PCN performance.

    RecommendationIndicator(s)Policy anchorData level
    Core20 list and resident reconciliation (p3)Core20 cohort (IMD quintile 1)Core20PLUS5 · 10YHP equity testPCN
    Mental health physical check recall (p4)Record of BMI in the last 12 months for patients on the MH register (denominator incl. PCAs)MHIS · From Harm to HopePCN
    Audit older hypertensive patients (p5)Last BP reading of patients (80+ yrs with hypertension) in the last 12 months is <= 150/90 mmHg (denominator incl. PCAs)Core20PLUS5 CVD · CVDPREVENT 2029PCN
    Childhood immunisation call and recall (p6)6-in-1 coverage at 12 months10YHP sickness to prevention · 95% targetPCN
    Early cancer pathway collaboration (p7)Cancers diagnosed at stage 1 or 2 (All cancer sites)—ICB
    Appointment booking audit (p9)GPPS last request led to a booked appointment10YHP, hospital to communityPractice
    Option 1 · Structured asthma annual review recall (p12)Asthma register · Asthma: QOF prevalence · Patients with Asthma: review in the last 12 months (denominator incl. PCAs)Core20PLUS5 respiratoryPCN
    Option 2 · COPD register and respiratory record review (p12)COPD register · COPD: QOF prevalence · COPD patients with a review in the last 12 monthsCore20PLUS5 approach · Tobacco and Vapes BillPCN
    Option 3 · Pharmacist-led lipid therapy recall audit (p12)CKD patients treated with lipid lowering therapy · Patients with diabetes and a history of CVD (excl. haem. stroke) treated with a statin (denominator incl. PCAs) · Patients with QRISK ≥ 20% treated with lipid lowering therapyCore20PLUS5 CVD · CVDPREVENT 2029PCN
    Sources & context

    Re-run this profile in 12 months to see whether the gaps have narrowed

    Powered by Coplug · Page 13 of 15
    14 / 15

    Data sources

    Data sources

    Every figure in this profile comes from a dataset below, at the level and period stated. Nothing published above PCN level is read as PCN performance.

    DatasetLevelPeriodUsed for
    Coplug indicator tables: census, deprivation and QOF measuresPCN & Practice2023 to 2025, projected to 2030; 2023 to 2024Pages 1, 2, 3, 4, 5, 6, 7, 8, 10, 12
    MHCLG, Rough sleeping snapshot in England: autumn 2025Local authorityAutumn 2025Pages 2, 4
    OHID, Fingertips diabetes by frailty status: HbA1c control (93712, 93713)PCN2024/25Pages 2, 4
    OHID, Fingertips falls: emergency admissions, 65+ and 65 to 79 (22401, 22402), accidental-fall deaths (94002)Local authority2024/25; 2022-24Pages 2, 4
    ONS, Census 2021 TS039: provision of unpaid care (age-standardised)Local authorityCensus 2021Pages 2, 4
    QOF registers, prevalence and care processes (Coplug indicator tables)Practice2023 to 2025, projected to 2030Pages 4, 5, 6, 7, 8, 10
    UKHSA, COVER supplementary GP data, childhood immunisation coverage, Q1 2025/26PCN & PracticeQ1 2025/26Pages 4, 6
    UKHSA, Seasonal influenza vaccine uptake in GP patients, 2025 to 2026Local authority2025/26 season to 28 Feb 2026Pages 4, 6
    NHS England, Cancer Waiting Times: July 2026 monthly time series with revisionsICB & ProviderJul 2026 (provisional)Pages 7, 8
    NHS England, Community Services Statistics (CSDS): June 2026 provisional experimental dataICB & Local authorityJun 2026 (provisional)Pages 7, 8
    NHS England, Monthly Diagnostics Waiting Times and Activity (DM01): provider by test, July 2026ProviderJul 2026Pages 7, 8
    National Disease Registration Service, Stage at diagnosis by cancer site in England, 2013 to 2022ICB2022Pages 7, 8
    NHS England / Ipsos, GP Patient Survey 2026: practice results (weighted)PracticeSurvey Jan-Apr 2026Page 9
    NHS England, Quality and Outcomes Framework 2025-26: achievement by practice and domainPractice2025/26Page 9
    NHS England, Quality and Outcomes Framework 2025-26: personalised care adjustments by practice and domainPractice2025/26Page 9
    Coplug indicator catalogue — definitions, cohorts, policy anchorsReferenceCurrentEvidence-base lines, page 13
    Sources & context

    Where a period is given as "as supplied", the source file did not state a vintage

    Powered by Coplug · Page 14 of 15
    15 / 15

    Methods, data-quality notes and limitations

    Methods, data-quality notes and limitations

    Methods

    Estimated gaps apply benchmark prevalence to the registered population and subtract the recorded register. They size the task; they are not confirmed missed patients.

    Percentage points are the difference between two rates; a relative change is that difference as a share of the starting rate. Register changes are relative, over three years.

    Forecasts to 2030 extend each indicator's current trajectory with no change in case-finding or service model: a baseline to act against, not a prediction.

    Core20 is the most deprived 20% nationally (IMD quintile 1). Practice shares are not additive to the PCN figure. Ethnic minority is 100% minus White. Local-authority averages are unweighted.

    Sources & context

    Estimates size the task; they are not confirmed missed patients

    Powered by Coplug · Page 15 of 15